TR200706209T1 - Controlled release formulations of alfuzosin. - Google Patents

Controlled release formulations of alfuzosin.

Info

Publication number
TR200706209T1
TR200706209T1 TR2007/06209T TR200706209T TR200706209T1 TR 200706209 T1 TR200706209 T1 TR 200706209T1 TR 2007/06209 T TR2007/06209 T TR 2007/06209T TR 200706209 T TR200706209 T TR 200706209T TR 200706209 T1 TR200706209 T1 TR 200706209T1
Authority
TR
Turkey
Prior art keywords
controlled release
alfuzosin
release formulations
treatment
pharmaceutical formulation
Prior art date
Application number
TR2007/06209T
Other languages
Turkish (tr)
Inventor
Niccolai Fabrizio
Ravelli Vittorino
Original Assignee
Ph&T Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ph&T Spa filed Critical Ph&T Spa
Publication of TR200706209T1 publication Critical patent/TR200706209T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Abstract

Alfuzosin hidroklorür içeren katı, kontrollü salınımlı farmasötik bir formülasyon ve bunun, prostat hipertrofisinin tedavisinde kullanımı.A solid controlled release pharmaceutical formulation containing alfuzosin hydrochloride and its use in the treatment of prostatic hypertrophy.

TR2007/06209T 2005-03-11 2006-03-06 Controlled release formulations of alfuzosin. TR200706209T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000391A ITMI20050391A1 (en) 2005-03-11 2005-03-11 CONTROLLED RELEASE FORMULATIONS OF ALFUZOSIN

Publications (1)

Publication Number Publication Date
TR200706209T1 true TR200706209T1 (en) 2007-12-24

Family

ID=36939083

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2007/06209T TR200706209T1 (en) 2005-03-11 2006-03-06 Controlled release formulations of alfuzosin.

Country Status (6)

Country Link
KR (1) KR20070110068A (en)
CN (1) CN101137351A (en)
IT (1) ITMI20050391A1 (en)
RU (1) RU2423107C2 (en)
TR (1) TR200706209T1 (en)
WO (1) WO2006094736A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
CN101095681B (en) * 2007-07-13 2011-04-20 沈阳药大制剂新技术有限公司 Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same
CN105287422A (en) * 2015-12-07 2016-02-03 黑龙江省智诚医药科技有限公司 Alfuzosin hydrochloride sustained release tablets and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752737B1 (en) * 1996-08-29 1998-10-02 Synthelabo CONTROLLED RELEASE TABLET OF ALFUZOSINE HYDROCHLORIDE
PT938318E (en) * 1996-08-29 2001-10-30 Jagotec Ag TABLET WITH CONTROLLED FREEDOM OF ALFUZOSINE CHLORIDRATE
FR2820319B3 (en) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals PROCESS FOR PRODUCING A FLOATING TABLET INCLUDING ALFUZOSINE AND TABLET OBTAINED

Also Published As

Publication number Publication date
KR20070110068A (en) 2007-11-15
ITMI20050391A1 (en) 2006-09-12
CN101137351A (en) 2008-03-05
RU2007133793A (en) 2009-03-20
RU2423107C2 (en) 2011-07-10
WO2006094736A3 (en) 2007-01-04
WO2006094736A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
MX2009004883A (en) Multi-substituted pyridyl sulfoximines and their use as insecticides.
BRPI0814102A2 (en) PELVIC IMPLANT, AND, KIT.
IL209494A (en) Insulin-oligomer monoconjugates, formulations and uses thereof
BRPI0618904A2 (en) compound, pharmaceutical composition, and compound use
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
CL2007002640A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007002642A1 (en) COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
ECSP109852A (en) USE OF HOMO AND COPOLYMERS FOR THE STABILIZATION OF FORMULATIONS OF ACTIVE PRINCIPLES
DK1723128T3 (en) Heteroarlurines and their use as glucokinase activators
MX2008007307A (en) Modified active-ingredient-containing pellets/capsules.
DK1753406T4 (en) COVERED TABLET FORMULATION AND PROCEDURE
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
DE602006004731D1 (en) Dry granulation composition containing emtricitabine and tenofovir DF
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
EA200801430A1 (en) TRIAZOLE DERIVATIVES
EP1731609A4 (en) Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
BRPI0619911A2 (en) compound, prodrug, pharmaceutical agent, and compound use
NO20081292L (en) Pentacyclic kinase inhibitors
HK1127995A1 (en) Phaseolus vulgaris extracts, their use, and formulations containing them
BRPI0615630A2 (en) pharmaceutical composition and use of sertindole
TR200706209T1 (en) Controlled release formulations of alfuzosin.
ATE417560T1 (en) SURGICAL NAIL